ClinicalTrials.gg
Active, not recruitingNCT07226882Updated May 6, 2026

A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

A Phase 3 interventional study of VLA15 and Placebo in Lyme Borreliosis, sponsored by Pfizer. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.

Enrollment
11th of 33
207 · median 72
Started
2025
with 2 others
Phase 3
10 of 54
1 open now
Primary completion
2028-01
later than 10 of 14 live
Registered
51st of 54
by date
Lead sponsor
8 of 54
Pfizer

Among the 54 studies in Lyme Disease with a site in United States, this one is the 11th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 10 of the 14 other live ones, and was the 51st registered.

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

Browse Lyme Disease studies →

Open to participants now

15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 44 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lyme Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the Lyme disease vaccine (called VLA15) when given at different time points.

This study is seeking participants who:

  • are generally healthy and between 18 and 44 years of age,
  • have never had a vaccine for Lyme disease before,
  • are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners, and
  • are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine.

All participants in this study will receive a total of 5 doses through a shot in the upper arm. Four doses will be the study vaccine (VLA15), and 1 dose will be saltwater.

The study will compare the experiences of people receiving the study vaccine at different time points. This will help see if the study vaccine is safe and will help understand its effect on the body.

Participants will take part in this study for about 2 years. During this time, the participants will have 11 planned visits - 8 will be at the study clinic and 3 will be done over the phone. The clinic visits may include having a health check, giving a small amount of blood (about 20 mL or 4 teaspoons), and getting the study vaccine or saltwater as a shot.

Read the detailed description

This is a Phase 3, randomized, parallel-group, placebo-controlled, double-blinded (third-party unblinded) study to evaluate the safety, tolerability, and immunogenicity of different vaccination schedules of the 6-valent OspA-based Lyme disease (LD) vaccine, VLA15, in healthy participants 18 through 44 years of age.

Participants will be randomized in a 1:1:1:1 ratio to 1 of the 4 parallel study groups. Each participant will receive 4 doses of VLA15 and 1 dose of placebo (saline) at different time points. This study will use an external data monitoring committee (EDMC). The EDMC is independent of the Pfizer study team and includes only external members. The EDMC charter describes the role of the EDMC in more detail.

Approximately 200 participants will be enrolled in the study.

Healthy individuals 18 through 44 years of age who are willing to comply with all study procedures and provide signed informed consent will be enrolled. Pregnant or breastfeeding individuals and fertile individuals who are unwilling or unable to use effective contraceptive methods as outlined in this protocol will not be enrolled. Individuals who have contraindication to vaccination, conditions or treatments that can inhibit the ability to mount an immune response to a vaccine, or other conditions that may increase the risk of study participation will be excluded from this study. Individuals who have previously received a licensed or investigational vaccine for LD will also be excluded from this study.

03

Conditions studied

  • Lyme Borreliosis

Browse trials for

Keywords

  • Lyme disease
  • Lyme Borreliosis, Nervous System
  • Lyme
  • Lyme Disease Vaccine
04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are healthy as determined by medical history and clinical judgment.
  • Participants willing and able to comply with all scheduled visits, IP receipt, and other procedures throughout the study.
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding participants.
  • Allergies or to vaccines or their components.
  • Health issues including: blood clotting deficiencies, immunodeficiencies, bone marrow disorder, or uncontrolled psychiatric conditions.
  • Receipt of therapies to treat , blood/plasma products and immunoglobulins, systemic and , or anticoagulant therapy in recent medical history.
  • Any prior Lyme disease vaccination, or recent or concurrent participation in a separate interventional study.
  • Staff or direct family of the study site staff and Sponsor.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants will receive 4 doses of VLA15 and 1 dose of placebo injection at different visits. Placebo will be given at Visit 3. Injections will be given as intramuscular shots.

    Biological: VLA15 · Biological: Placebo

  • Experimental
    Group 2

    Participants will receive 4 doses of VLA15 and 1 dose of placebo injection at different visits. Placebo will be given at Visit 5. Injections will be given as intramuscular shots.

    Biological: VLA15 · Biological: Placebo

  • Experimental
    Group 3

    Participants will receive 4 doses of VLA15 and 1 dose of placebo injection at different visits. Placebo will be given at Visit 7. Injections will be given as intramuscular shots.

    Biological: VLA15 · Biological: Placebo

  • Experimental
    Group 4

    Participants will receive 4 doses of VLA15 and 1 dose of placebo injection at different visits. Placebo will be given at Visit 9. Injections will be given as intramuscular shots.

    Biological: VLA15 · Biological: Placebo

Interventions

  • BiologicalVLA15

    Participants will receive IM injection of 6-valent OspA-based Lyme disease vaccine

  • BiologicalPlacebo

    Saline

06

What researchers measure

Primary outcomes

  1. Geometric Mean Concentration (GMC) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG)

    Time frame: At 1 month after the fourth VLA15 dose

  2. Geometric Mean Fold Rise (GMFR) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) Concentrations

    Time frame: Before the first dose to 1 month after the fourth VLA15 dose

  3. Sero-Response Rate Based on Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) Concentrations.

    Time frame: Before the first dose to 1 month after the fourth VLA15 dose

  4. Percentage of Participants With Local Reactions For Each Group

    Time frame: Within 7 days after each vaccination

  5. Percentage of Participants With Systemic Events For Each Group

    Time frame: Within 7 days after each vaccination

  6. Percentage of Participants With Adverse Events (AEs) For Each Group

    Time frame: Within 1 month after each vaccination

  7. Percentage of Participants With Serious Adverse Events (SAEs) For Each Group

    Time frame: From the time the participant provides informed consent up to approximately 6 months after the last vaccination

  8. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) For Each Group

    Time frame: From the time the participant provides informed consent up to approximately 6 months after the last vaccination

Secondary outcomes

  1. Geometric Mean Concentration (GMC) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG)

    Time frame: At 1 month after the third VLA15 dose

  2. Geometric Mean Fold Rise (GMFR) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) Concentrations

    Time frame: Before the first dose to 1 month after the third VLA15 dose

  3. Sero-Response Rate Based on Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) Concentrations.

    Time frame: Before the first dose to 1 month after the third VLA15 dose

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jan 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2025
First posted
Nov 12, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Jan 27, 2028
CompletionEst.
Jan 27, 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07226882
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 12, 2025
Start date
Nov 19, 2025
Primary completion
Jan 27, 2028 (estimated)
Completion
Jan 27, 2028 (estimated)
Last update
May 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VLA15

Start the discussion